BioNTech SE

Welcome to BioNTech's second quarter 2026 earnings call. I will hand the call over to Doug Maffei, Vice President Strategy and Investor Relations. Please go ahead.

Thank you, operator. Good morning and good afternoon. Thank you for joining BioNTech's second quarter 2026 earnings call. As a reminder, the slides we will be using during this call and the corresponding press release can be found in the investor section of our website. On the next slide, you will see our forward-looking statements disclaimer. Additional information about these statements and other risks are described in our filings with the US Securities and Exchange Commission, or SEC. Forward-looking statements on this call are subject to significant risks and uncertainties and speak only as of the date of this conference call. We undertake no obligation to update or revise any of these statements. On slide three, you can see the agenda for today's call. I'm joined by the following members of BioNTech's management team. Ugur Sahin, chief executive officer and co-founder, Ozlem Tureci, chief medical officer and co-founder and Ramon Zapata, chief financial officer. Also available for the Q&A portion of the call is Annemarie Hanekamp, Chief Commercial Officer. Related to yesterday's Chief Executive Officer announcement, we will also be joined today by Helmut Jägle, Chairman of BioNTech Supervisory Board. With this, I will hand the call over to Helmut.

Thank you, Doug, and good morning, everyone. Before we begin with a business update from the Management Board, I would like to provide further color on the appointment of BioNTech's next chief executive officer. As announced yesterday, Guido Oelkers will take office as CEO as of February 1st at the latest. From the outset, the supervisory board's CEO search was guided by three clear priorities. Proven strategic leadership, the ability to scale a global biopharmaceutical business and a strong track record, of building and growing innovation-driven science-based organizations. Guido is an excellent fit on all three dimensions. Most recently, as CEO of Zobe, he more than quadrupled the company's revenues over nine years by strengthening its global capabilities and maximizing the value of his late-stage pipeline. He brings deep expertise in launching and commercializing innovative products with a focus on the US market, as well as extensive leadership experience across Europe and Asia Pacific. The supervisory board believes that Guido is the right leader for BioNTech's next phase. His expertise in scaling innovative organizations in a focused and capital-efficient manner combined with his deep knowledge of the markets most relevant to BioNTech will position the company well to deliver on its key objectives evolve into a multi-product biopharmaceutical company and continue its remarkable success story. With that, I would like to hand over to Ugur and will be available for questions during the Q&A at the end of the call.